Editorial: Translational Research and Drug Repurposing for Non-Communicable Diseases (NCDs)

Editorial on the Research Topic
Translational Research and Drug Repurposing for Non-Communicable Diseases (NCDs)

Background

Translational research involves scientific (collaborative) explorations aimed at putting investigative findings in the basic medical sciences into useful applications in clinical practice for the purpose of prevention, diagnosis, and therapeutic management of disease conditions. This “bench to bedside” approach facilitates the emergence of new medications. Drug repurposing (repositioning) is a relatively recent but promising evolution within this context that refers to investigational initiatives to put currently approved drugs, agents previously withdrawn, and relatively out-dated drugs to new therapeutic uses in the clinic. Reported examples of successes in drug repurposing include sildenafil (original indication (OI)—angina; new indication (NI)—erectile dysfunction); thalidomide (OI—morning sickness; NI—erythema nodosum leprosum and multiple myeloma); aspirin (OI—analgesia; NI—colorectal cancer); ketoconazole (OI—fungal infections; NI—Cushing syndrome); and topiramate (OI—epilepsy; NI—obesity). In respect of the ongoing Coronavirus Disease 2019 (COVID-19) pandemic, clinical trials of drugs approved for other indications, including remdesivir, ivermectin, dexamethasone, toclizumab, mavrilimumab, baricitinib, baricitinib with remdesivir, etc., have shown some beneficial effects (Chakraborty et al., 2021).

Goal

The incidence, morbidity, and mortality associated with non-communicable diseases (NCDs) have been on the increase worldwide over the years. Cardiovascular diseases, chronic respiratory diseases, cancers, diabetes and mental illnesses have been reported to be major contributors to the NCDs burden in developing and developed countries. In most cases, cures are unavailable and current palliative therapeutic interventions are associated with worrisome untoward effects. In fact, it has also been recently shown that NCDs as pre-existing conditions are major contributors to the severity and fatality associated with COVID-19 worldwide. Drug repurposing in translational research offers a great opportunity for widening the therapeutic options for the treatment of NCDs. The advantages over the usual drug discovery and development pipeline include lower associated risks and conservation of time and cost.

Scope

Our research topic provided a focused platform for researchers in translational and drug repurposing research to share their findings as regards NCDs and to showcase potential leads and alternate therapeutic options towards reducing the burden of NCDs worldwide. The scope included reviews and research articles on in silico, in vitro and in vivo experimentations, or combinations thereof, with potential impact on the prospect of finding novel treatments for NCDs, including cardiovascular diseases, chronic respiratory diseases, cancers, diabetes, mental illnesses, etc.

Overview of Contributions

Trastuzumab (TZM) is a monoclonal antibody employed in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer (Waller et al., 2021). Cardiac dysfunction is a cause for concern in the use of this biologic. This effect has been linked to the downregulation of neuregulin-1 (NRG-1) which plays a vital role in the activation of cell survival pathways in cardiomyocytes and the maintenance of cardiac function (Zeglinski et al., 2011). Olorundare et al. evaluated the therapeutic potentials of selected antihypertensive medications (amlodipine, lisinopril, valsartan, and their fixed-dose combinations) in TZM-induced cardiotoxicity. Parameters assessed include markers of cardiac injury and oxidative stress, along with profiling of lipids and histopathological and immunohistochemical assessments. The authors reported that treatment with the antihypertensive drugs and their fixed-dose combinations reversed derangement in biochemical parameters, and histopathological and immunohistochemical presentations induced by TZM. The beneficial effect of the interventions was linked to antiapoptotic and oxidative stress inhibition mechanisms. However, cause for concern was raised with valsartan/lisinopril fixed-dose combination in terms of associated hyperlipidemia, increased atherogenic index and coronary artery index values, and coronary artery cartilaginous metaplasia.

Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by initial deficits in the ability to encode and store new memories and later progressive changes in cognition and behaviour, in which symptomatic treatment offers marginal benefit on cognition, but the condition seriously warrants the emergence of disease-modifying therapies (Soria Lopez et al., 2019). The pathophysiology of AD relates to beta-amyloid deposition and neurofibrillary tangles in association with the triggering of a complex cascade of events (leading to neuronal cell death, loss of neuronal synapses and progressive neurotransmitter deficits), sustained immune response and inflammation, and significant prion-invoked increase in abnormal proteins, leading to brain damage (Kinney et al., 2018). Xu et al. via enrichment analysis of drug-induced transcriptional profiles of pathways based on AD-associated risk genes identified from genome-wide association analyses (GWAS) and single-cell transcriptomic studies sought to identify potential anti-AD agents. Their study unveiled ellipticine, alsterpaullone, tomelukast, ginkgolide A, chrysin, ouabain, sulindac sulfide and lorglumide as potential anti-AD agents. The authors suggested further experimental validation and that their approach may be applied in repurposing drugs for other neurological disorders.

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy responsible for significant cancer-related mortality worldwide and with increasing numbers in terms of incidence and mortality, despite various advances (Balogh et al., 2016). According to Kirstein and Wirth (2020), interdisciplinary and multimodal treatment strategies are essential for successful therapy of HCC, including surgical interventions, local ablative therapies, locoregional therapies and systemic therapies (sorafenib—multityrosine kinase inhibitor; lenvatinib, regorafenib and cabozantinib—tyrosine kinase inhibitors; ramucirumab—VEGF-receptor inhibitor, etc.). Abd El-Fattah et al. explored the potential of sitagliptin (an antidiabetic drug) for the management of HCC using the N-nitrosodiethylamine-induced HCC mouse model. The authors established that sitagliptin inhibited HIF-1α activation via interference with the AKT-AMPKα-mTOR axis and interruption of IKKβ, P38α and ERK1/2 signals. Sitagliptin demonstrated antiproliferative (inhibition of angiogenesis and stimulation of apoptosis), anti-inflammatory (diminution of TNF-α level and downregulation of MCP-1 gene expression) and antifibrotic (reduction in TGF-β level) effects. Their findings provide justification for the repurposing of sitagliptin for the treatment of HCC.

Alam et al. in a bid to identify drugs that could be repurposed across a range of seemingly unrelated conditions adopted an integrative network approach to delineate genetic overlaps in pathophysiology between tuberculosis (TB)—an infectious disease—and non-communicable diseases (NCDs) such as Parkinson’s disease, cardiovascular disease, diabetes mellitus, rheumatoid arthritis and lung cancer. Through their interaction network of disease genes, authors identified 86 hub genes linked to inflammatory/immune and stress responses as commonly associated with TB and its overlapping NCDs. A network of drugs targeting those genes was then built, and their drug-target interactions were explored. Such drugs or drug combinations targeting the hub proteins are suggested to have potential to improve clinical conditions in co-morbidities involving TB and overlapping NCDs, and could potentiate or synergise with one another to achieve better outcomes. These possibilities represent a promising future application of drug repurposing (drug repositioning).

Conclusion

The articles published within this research topic capture the unique and exceptional promise of drug repurposing in NCDs, as well as showcasing the multidisciplinary approaches and experimental tools and platforms being deployed to advance drug repurposing research. The collection enables a reader to appreciate how drug repurposing is revolutionising drug discovery and development. While maximising the benefits of drug repurposing certainly requires further integration of basic research and clinical practice (bench-to-bedside and bedside-to-bench), our research topic signifies we could be witnessing a new era in finding relevant drugs in a more sustainable manner—at least, with respect to time and speed—to manage several disease conditions.

Author Contributions

Content was conceived by all authors; AJA and AAF drafted the manuscript; all authors reviewed and approved the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

Authors appreciate the review help of Basiru O. Ajiboye (Afe Babalola University, Nigeria), Ahmed Elberry (Beni-Suef University, Egypt), Qing Lyu (Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, China), Anjun Ma (The Ohio State University, U.S.), VS (University of Pretoria, South Africa), Lu Qin (Penn State Milton S. Hershey Medical Center, U.S.), Sadiq Umar (University of Illinois at Chicago, U.S.) and Sushila Rigas (The Open University, United Kingdom).

References

Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., et al. (2016). Hepatocellular Carcinoma: A Review. J. Hepatocell. Carcinoma. 3, 41–53. doi:10.2147/JHC.S61146

CrossRef Full Text | Google Scholar

Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., and Lee, S. S. (2021). The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. Front. Pharmacol. 12, 704205. doi:10.3389/fphar.2021.704205

PubMed Abstract | CrossRef Full Text | Google Scholar

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., and Lamb, B. T. (2018). Inflammation as a central Mechanism in Alzheimer's Disease. Alzheimers Dement (N Y) 4, 575–590. doi:10.1016/j.trci.2018.06.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Kirstein, M. M., and Wirth, T. C. (2020). Multimodale Therapie des hepatozellulären Karzinoms [Multimodal treatment of hepatocellular carcinoma]. Internist (Berl) 61 (2), 164–169. doi:10.1007/s00108-019-00722-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Soria Lopez, J. A., González, H. M., and Léger, G. C. (2019). Alzheimer's Disease. Handb Clin. Neurol. 167, 231–255. doi:10.1016/B978-0-12-804766-8.00013-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Waller, C. F., Möbius, J., and Fuentes-Alburo, A. (2021). Intravenous and Subcutaneous Formulations of Trastuzumab, and Trastuzumab Biosimilars: Implications for Clinical Practice. Br. J. Cancer 124 (8), 1346–1352. doi:10.1038/s41416-020-01255-z

CrossRef Full Text | Google Scholar

Zeglinski, M., Ludke, A., Jassal, D. S., and Singal, P. K. (2011). Trastuzumab-induced Cardiac Dysfunction: A ‘Dual-Hit'. Exp. Clin. Cardiol. 16, 70–74.

PubMed Abstract | Google Scholar